Safety, Pharmacokinetic, and Functional Effects of the Nogo-A Monoclonal Antibody in Amyotrophic Lateral Sclerosis: A Randomized, First-In-Human Clinical Trial

Therapeutic neuroprotective agents for amyotrophic lateral sclerosis

(2013) Rachna S. Pandya et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial

(2013) Merit E Cudkowicz et al.   LANCET NEUROLOGY

Controversies and priorities in amyotrophic lateral sclerosis

(2013) Martin R Turner et al.   LANCET NEUROLOGY

The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis

(2011) Merit Cudkowicz et al.   NATURE MEDICINE

Multipoint incremental motor unit number estimation as an outcome measure in ALS

(2011) J. M. Shefner et al.   NEUROLOGY

Quality control of vital capacity as a primary outcome measure during phase III therapeutic clinical trial in amyotrophic lateral sclerosis

(2010) Mohammed Sanjak et al.   Amyotrophic Lateral Sclerosis

A Review of the Neural Mechanisms of Action and Clinical Efficiency of Riluzole in Treating Amyotrophic Lateral Sclerosis: What have we Learned in the Last Decade?

(2010) Mark C. Bellingham   CNS Neuroscience & Therapeutics

Functions of Nogo proteins and their receptors in the nervous system

(2010) Martin E. Schwab   NATURE REVIEWS NEUROSCIENCE

Practice Parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

(2009) R. G. Miller et al.   NEUROLOGY